Key facts
- Notable investors include Innoangel Fund, Beijing State-owned Capital Operation and Management, Frees Fund, Beishang Capital Management (Beijing).
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Dingou Biopharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Dingou Biopharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dingou Biopharmaceutical
Operator of a biopharmaceutical firm intended to advance allergen-specific diagnosis and treatment for individuals with allergic conditions. The company offers pollen-specific desensitization injections and diagnostic reagents, enabling patients with allergic diseases to receive targeted care and improved therapeutic outcomes.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2024
- Ownership
- Privately Held (backing)
Dingou Biopharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dingou Biopharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dingou Biopharmaceutical in its N-PORT filings yet. We sweep new filings monthly.